CSPC PHARMA (01093): Potent aldosterone synthase inhibitor (SYH2072 tablet) granted clinical trial approval in China.

CSPC Pharma (01093) announced that the group's newly developed Class 1 drug, a potent aldo-keto reductase inhibitor (SYH2072 tablets), has been approved by the National Medical Products Administration of the People's Republic of China for clinical trials in China. This product is a highly selective and potent aldo-keto reductase inhibitor (ASI) that can effectively reduce plasma aldosterone levels without affecting cortisol levels. The approved clinical indications for this product are uncontrolled hypertension and primary aldosteronism. Preclinical studies have shown that the product selectively inhibits aldosterone synthase activity, significantly lowers plasma aldosterone levels in animal disease models, and dose-dependently reduces blood pressure in hypertension models while not affecting cortisol levels. The product has good pharmacokinetic (PK) properties and safety, making it a potential best-in-class drug. The group has already submitted multiple patent applications for this product domestically and internationally. Given the broad clinical demand for aldosterone synthase inhibitors, this product has high clinical development value and is expected to provide new treatment options for patients with uncontrolled hypertension and primary aldosteronism.